{"pmid":32350861,"title":"COVID-19: a defining moment for clinical pharmacology?","text":["COVID-19: a defining moment for clinical pharmacology?","COVID-19 is overshadowing society across the world and it will redefine many aspects of how we live and work in the future. In a crisis, people are rightly looking for solutions from their leaders and experts and their response and actions will define them for years to come. COVID-19 may also be such a defining moment for clinical pharmacology in terms of its role in drug development and therapy. Though most drug development takes years from discovery to approval, for the COVID-19 pandemic, drug development is on a fundamentally different timeline.","Clin Pharmacol Ther","van, Piet H","der Graaf","Giacomini, Kathleen M","32350861"],"abstract":["COVID-19 is overshadowing society across the world and it will redefine many aspects of how we live and work in the future. In a crisis, people are rightly looking for solutions from their leaders and experts and their response and actions will define them for years to come. COVID-19 may also be such a defining moment for clinical pharmacology in terms of its role in drug development and therapy. Though most drug development takes years from discovery to approval, for the COVID-19 pandemic, drug development is on a fundamentally different timeline."],"journal":"Clin Pharmacol Ther","authors":["van, Piet H","der Graaf","Giacomini, Kathleen M"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32350861","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/cpt.1876","topics":["Treatment"],"weight":1,"_version_":1666138495642501120,"score":9.490897,"similar":[{"pmid":32329520,"title":"Current pharmacological treatments for COVID-19: what's next?","text":["Current pharmacological treatments for COVID-19: what's next?","Starting from December 2019 the novel SARS-Cov-2 has spread all over the world, being recognized as the causing agent of COVID-19. Since nowadays no specific drug therapies neither vaccines are available for the treatment of COVID-19, drug repositioning may offer a strategy to efficiently control the clinical course of the disease and the spread of the outbreak. In this paper we aim to describe the main pharmacological properties, including data on mechanism of action, safety concerns and drug-drug interactions, of drugs currently administered in patients with COVID-19, focusing on antivirals and drugs with immune-modulatory and/or anti-inflammatory properties. Where available, data from clinical trials involving patients with COVID-19 were reported. Several studies have been registered worldwide and a number of drugs were repurposed to face the new health emergency of COVID-19. For many of these drugs, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab, preliminary clinical trials seem to support their benefit in improving patients' clinical conditions. However, adequate clinical trials are necessary to reach any firm conclusion on the efficacy and safety profiles of these compounds. Even though drug repurposing is necessary, it requires caution. Too many drugs that are currently tested in patients with COVID-19 have peculiar safety profiles. In conclusion, while waiting for the development of effective preventive measures, such as vaccines, many clinical trials on drugs belonging to different therapeutic classes are currently underway. It is conceivable that very soon their results will help us in defining the best way to treat COVID-19 and reducing its symptoms and complications.","Br J Pharmacol","Scavone, Cristina","Brusco, Simona","Bertini, Michele","Sportiello, Liberata","Rafaniello, Concetta","Zoccoli, Alice","Berrino, Liberato","Racagni, Giorgio","Rossi, Francesco","Capuano, Annalisa","32329520"],"abstract":["Starting from December 2019 the novel SARS-Cov-2 has spread all over the world, being recognized as the causing agent of COVID-19. Since nowadays no specific drug therapies neither vaccines are available for the treatment of COVID-19, drug repositioning may offer a strategy to efficiently control the clinical course of the disease and the spread of the outbreak. In this paper we aim to describe the main pharmacological properties, including data on mechanism of action, safety concerns and drug-drug interactions, of drugs currently administered in patients with COVID-19, focusing on antivirals and drugs with immune-modulatory and/or anti-inflammatory properties. Where available, data from clinical trials involving patients with COVID-19 were reported. Several studies have been registered worldwide and a number of drugs were repurposed to face the new health emergency of COVID-19. For many of these drugs, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab, preliminary clinical trials seem to support their benefit in improving patients' clinical conditions. However, adequate clinical trials are necessary to reach any firm conclusion on the efficacy and safety profiles of these compounds. Even though drug repurposing is necessary, it requires caution. Too many drugs that are currently tested in patients with COVID-19 have peculiar safety profiles. In conclusion, while waiting for the development of effective preventive measures, such as vaccines, many clinical trials on drugs belonging to different therapeutic classes are currently underway. It is conceivable that very soon their results will help us in defining the best way to treat COVID-19 and reducing its symptoms and complications."],"journal":"Br J Pharmacol","authors":["Scavone, Cristina","Brusco, Simona","Bertini, Michele","Sportiello, Liberata","Rafaniello, Concetta","Zoccoli, Alice","Berrino, Liberato","Racagni, Giorgio","Rossi, Francesco","Capuano, Annalisa"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329520","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/bph.15072","keywords":["covid-19","anti-inflammatory agents","antivirals","clinical practice","clinical research","immuno-modulatory agents","literature review","pharmacological treatments"],"e_drugs":["remdesivir","tocilizumab","lopinavir-ritonavir drug combination","favipiravir"],"topics":["Treatment"],"weight":1,"_version_":1666138494591827971,"score":98.556755},{"pmid":32356569,"title":"Challenges in Drug Development Posed by the COVID-19 Pandemic: An Opportunity for Clinical Pharmacology.","text":["Challenges in Drug Development Posed by the COVID-19 Pandemic: An Opportunity for Clinical Pharmacology.","The unprecedented challenges posed by the COVID-19 pandemic highlight the urgency for applying clinical pharmacology and model-informed drug development in (i) dosage optimization for COVID-19 therapies, (ii) approaching therapeutic dilemmas in clinical trial settings, and (iii) maximizing value of information from impacted non-COVID-19 trials. More than ever, we have a responsibility for adaptive evidence synthesis with a Totality of Evidence mindset in this race against time across biomedical research, clinical practice, drug development and regulation.","Clin Pharmacol Ther","Venkatakrishnan, Karthik","Yalkinoglu, Oezkan","Dong, Jennifer Q","Benincosa, Lisa J","32356569"],"abstract":["The unprecedented challenges posed by the COVID-19 pandemic highlight the urgency for applying clinical pharmacology and model-informed drug development in (i) dosage optimization for COVID-19 therapies, (ii) approaching therapeutic dilemmas in clinical trial settings, and (iii) maximizing value of information from impacted non-COVID-19 trials. More than ever, we have a responsibility for adaptive evidence synthesis with a Totality of Evidence mindset in this race against time across biomedical research, clinical practice, drug development and regulation."],"journal":"Clin Pharmacol Ther","authors":["Venkatakrishnan, Karthik","Yalkinoglu, Oezkan","Dong, Jennifer Q","Benincosa, Lisa J"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32356569","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/cpt.1879","keywords":["covid-19","clinical trials","dose","drug-drug interactions","global health","model-informed drug development","translational medicine"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1666138495226216448,"score":88.78395},{"pmid":32394481,"title":"Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID-19 pandemic.","text":["Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID-19 pandemic.","On March 16, 2020, the French Society of Pharmacology and Therapeutics put online a national Question and Answer (Q&A) website, https://sfpt-fr.org/covid19 on the proper use of drugs during the COVID-19 pandemic. The working group \"Drugs and COVID-19\" was composed of a scientific council, an editorial team and experts in the field. The first questions were posted online during the first evening of home-confinement in France, March 17, 2020. Six weeks later, 140 Q&As have been posted. Questions on the controversial use of hydroxychloroquine and to a lesser extent concerning azithromycin have been the most consulted Q&As. Q&As has been consulted 226,014 times in 41 days. This large visibility was obtained through an early communication on Twitter, Facebook, traditional print and web media. In addition, an early communication through the French Ministry of Health and the French National Agency for Medicines and Health Products Safety ANSM had a large impact in terms of daily number of views. There is a pressing need to sustain a public drug information service combining the expertise of scholarly pharmacology societies, pharmacovigilance network, and the Ministry of Health to quickly provide understandable, clear, expert answers to the general population's concerns regarding COVID-19 and drug use and to counter fake news.","Fundam Clin Pharmacol","Larrouquere, Louis","Gabin, Manon","Poingt, Emmanuelle","Mouffak, Amelle","Hlavaty, Alex","Lepelley, Marion","Khouri, Charles","Bellier, Alexandre","Alexandre, Joachim","Bedouch, Pierrick","Bertoletti, Laurent","Bordet, Regis","Bouhanick, Beatrice","Jonville-Bera, Annie-Pierre","Laporte, Silvy","Le Jeunne, Claire","Letinier, Louis","Micallef, Joelle","Naudet, Florian","Roustit, Matthieu","Molimard, Mathieu","Richard, Vincent","Cracowski, Jean-Luc","32394481"],"abstract":["On March 16, 2020, the French Society of Pharmacology and Therapeutics put online a national Question and Answer (Q&A) website, https://sfpt-fr.org/covid19 on the proper use of drugs during the COVID-19 pandemic. The working group \"Drugs and COVID-19\" was composed of a scientific council, an editorial team and experts in the field. The first questions were posted online during the first evening of home-confinement in France, March 17, 2020. Six weeks later, 140 Q&As have been posted. Questions on the controversial use of hydroxychloroquine and to a lesser extent concerning azithromycin have been the most consulted Q&As. Q&As has been consulted 226,014 times in 41 days. This large visibility was obtained through an early communication on Twitter, Facebook, traditional print and web media. In addition, an early communication through the French Ministry of Health and the French National Agency for Medicines and Health Products Safety ANSM had a large impact in terms of daily number of views. There is a pressing need to sustain a public drug information service combining the expertise of scholarly pharmacology societies, pharmacovigilance network, and the Ministry of Health to quickly provide understandable, clear, expert answers to the general population's concerns regarding COVID-19 and drug use and to counter fake news."],"journal":"Fundam Clin Pharmacol","authors":["Larrouquere, Louis","Gabin, Manon","Poingt, Emmanuelle","Mouffak, Amelle","Hlavaty, Alex","Lepelley, Marion","Khouri, Charles","Bellier, Alexandre","Alexandre, Joachim","Bedouch, Pierrick","Bertoletti, Laurent","Bordet, Regis","Bouhanick, Beatrice","Jonville-Bera, Annie-Pierre","Laporte, Silvy","Le Jeunne, Claire","Letinier, Louis","Micallef, Joelle","Naudet, Florian","Roustit, Matthieu","Molimard, Mathieu","Richard, Vincent","Cracowski, Jean-Luc"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32394481","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/fcp.12564","locations":["France"],"countries":["France"],"countries_codes":["FRA|France"],"e_drugs":["Hydroxychloroquine","Azithromycin"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1666627827995246594,"score":86.71958},{"pmid":32247927,"pmcid":"PMC7151266","title":"Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence.","text":["Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence.","The novel coronavirus infection that initially found at the end of 2019 has attracted great attention. So far, the number of infectious cases has increased globally to more than 100 thousand and the outbreak has been defined as a pandemic situation, but there are still no \"specific drug\" available. Relevant reports have pointed out the novel coronavirus has 80% homology with SARS. In the difficulty where new synthesized drug cannot be applied immediately to patients, \"conventional drug in new use\" becomes a feasible solution. The first medication experience of the recovered patients in the US has led remdesivir to be the \"specific drug\". China has also taken immediate action to put remdesivir into clinical trials with the purpose of applying it into clinical therapeutics for Corona Virus Disease 2019 (COVID-19). We started from the structure, immunogenicity, and pathogenesis of coronavirus infections of the novel coronavirus. Further, we analyzed the pharmacological actions and previous trials of remdesivir to identify the feasibility of conducting experiments on COVID-19.","Travel Med Infect Dis","Cao, Yu-Chen","Deng, Qi-Xin","Dai, Shi-Xue","32247927"],"abstract":["The novel coronavirus infection that initially found at the end of 2019 has attracted great attention. So far, the number of infectious cases has increased globally to more than 100 thousand and the outbreak has been defined as a pandemic situation, but there are still no \"specific drug\" available. Relevant reports have pointed out the novel coronavirus has 80% homology with SARS. In the difficulty where new synthesized drug cannot be applied immediately to patients, \"conventional drug in new use\" becomes a feasible solution. The first medication experience of the recovered patients in the US has led remdesivir to be the \"specific drug\". China has also taken immediate action to put remdesivir into clinical trials with the purpose of applying it into clinical therapeutics for Corona Virus Disease 2019 (COVID-19). We started from the structure, immunogenicity, and pathogenesis of coronavirus infections of the novel coronavirus. Further, we analyzed the pharmacological actions and previous trials of remdesivir to identify the feasibility of conducting experiments on COVID-19."],"journal":"Travel Med Infect Dis","authors":["Cao, Yu-Chen","Deng, Qi-Xin","Dai, Shi-Xue"],"date":"2020-04-06T11:00:00Z","year":2020,"_id":"32247927","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.tmaid.2020.101647","keywords":["corona virus disease 2019","phase iii clinical trial","remdesivir","severe acute respiratory syndrome coronavirus 2"],"locations":["US","China"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"e_drugs":["remdesivir"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138491991359491,"score":85.31549},{"pmid":32358833,"title":"A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development. IUPHAR review \"XXX\".","text":["A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development. IUPHAR review \"XXX\".","In this review, we identify opportunities for drug discovery in the treatment of COVID-19 and in so doing, provide a rational roadmap whereby pharmacology and pharmacologists can mitigate against the global pandemic. We assess the scope for targetting key host and viral targets in the mid-term, by first screening these targets against drugs already licensed; an agenda for drug re-purposing, which should allow rapid translation to clinical trials. A simultaneous, multi-pronged approach using conventional drug discovery methodologies aimed at discovering novel chemical and biological means targetting a short-list of host and viral entities should extend the arsenal of anti-SARS-CoV-2 agents. This longer-term strategy would provide a deeper pool of drug choices for future-proofing against acquired drug resistance. Second, there will be further viral threats, which will inevitably evade existing vaccines. This will require a coherent therapeutic strategy which pharmacology and pharmacologists are best placed to provide.","Br J Pharmacol","Alexander, S P H","Armstrong, J","Davenport, A P","Davies, J","Faccenda, E","Harding, S D","Levi-Schaffer, F","Maguire, J J","Pawson, A J","Southan, C","Spedding, M J","32358833"],"abstract":["In this review, we identify opportunities for drug discovery in the treatment of COVID-19 and in so doing, provide a rational roadmap whereby pharmacology and pharmacologists can mitigate against the global pandemic. We assess the scope for targetting key host and viral targets in the mid-term, by first screening these targets against drugs already licensed; an agenda for drug re-purposing, which should allow rapid translation to clinical trials. A simultaneous, multi-pronged approach using conventional drug discovery methodologies aimed at discovering novel chemical and biological means targetting a short-list of host and viral entities should extend the arsenal of anti-SARS-CoV-2 agents. This longer-term strategy would provide a deeper pool of drug choices for future-proofing against acquired drug resistance. Second, there will be further viral threats, which will inevitably evade existing vaccines. This will require a coherent therapeutic strategy which pharmacology and pharmacologists are best placed to provide."],"journal":"Br J Pharmacol","authors":["Alexander, S P H","Armstrong, J","Davenport, A P","Davies, J","Faccenda, E","Harding, S D","Levi-Schaffer, F","Maguire, J J","Pawson, A J","Southan, C","Spedding, M J"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32358833","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/bph.15094","keywords":["covid-19","rna polymerase","sars-cov-2","proteinase"],"topics":["Treatment"],"weight":1,"_version_":1666138495333171201,"score":83.929245}]}